Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Paramora Holding
Delaware, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Paramora Holding is a biotechnology investment and asset holding company that is a key partner in the development of therapies for myeloproliferative neoplasms (MPNs). It is a party to a major antibody discovery and option agreement with Paragon Therapeutics and Galecto (following Galecto's acquisition of Damora Therapeutics), focusing on antibody candidates like DMR-001 that target mutant calreticulin (mutCALR).
- Therapeutic areas
- OncologyHematology
- Modalities
- Monoclonal antibody
- Industry
- Investors
02
Partnerships
Paragon TherapeuticsGalectoFairmount Funds Management
Beyond the preview
Go deeper on Paramora Holding.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Paramora Holding.